Neuburgh Advisers’s NovoCure NVCR Stock Holding History

Neuburgh Advisers’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-17,238	Closed	-$376K	–	896
2018 Q1	$376K	Hold	17,238	–	–	0.01%	479
2017 Q4	$348K	Hold	17,238	–	–	0.01%	514
2017 Q3	$342K	Hold	17,238	–	–	0.01%	477
2017 Q2	$298K	Hold	17,238	–	–	0.01%	487
2017 Q1	$140K	Hold	17,238	–	–	0.01%	559
2016 Q4	$135K	Buy	+17,238	New	+$139K	0.01%	535

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Neuburgh Advisers's NVCR Position: Q2 2018 in Review

Neuburgh Advisers sold out of NovoCure (NVCR) in Q2 2018, closing a stake of 17,238 shares — an estimated $376K sold.

Neuburgh Advisers first reported a position in NVCR in Q4 2016 and held it in 6 quarters. The position peaked at $376K in Q1 2018. 161 funds tracked by Wall St. Rank hold NVCR as of Q2 2018.

Neuburgh Advisers reported no remaining NovoCure position as of Q2 2018 after selling out during the quarter.
Neuburgh Advisers sold 17,238 NovoCure shares in Q2 2018, an estimated $376K.
Neuburgh Advisers first reported a position in NovoCure in Q4 2016 and held it in 6 quarters.
Neuburgh Advisers's NovoCure position peaked at $376K in Q1 2018.
161 funds tracked by Wall St. Rank held NovoCure as of Q2 2018.

Based on Neuburgh Advisers's 13F filing for Q2 2018, filed 10 Aug 2018.